Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...

Issued on behalf of Oncolytics Biotech Inc. "With positive BRACELET-1 results, we have two randomized phase two studies confirming pelareorep's potential in HR+/HER2- metastatic breast cancer,” said ...

Scotiabank analyst George Farmer lowered the firm’s price target on Syndax (SNDX) to $18 from $23 and keeps a Sector Perform rating on ...

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

UBS has recently initiated Syndax Pharmaceuticals Inc (SNDX) stock to Buy rating, as announced on October 24, 2024, according to Finviz. Earlier, on June 28, 2024, Jefferies had initiated the stock to ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...

Despite the promising data, Syndax Pharmaceuticals saw its stock plummet by -21.49% in premarket trading after the latest update on its AUGMENT-101 trial. As of Tuesday morning, the stock was trading ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...